Overview

A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: - How much effect AP-306 has assessed by blood phosphorus lowering; - How safe and tolerable AP-306 is. Participants will receive either following treatments: - AP-306, and - Sevelamer carbonate.
Phase:
Phase 2
Details
Lead Sponsor:
Alebund Pharmaceuticals
Treatments:
Sevelamer